Frequently Asked Questions Is IGF-1 LR3 a controlled substance in 2026
Severe abdominal pain in particular should be reported promptly
These qualifying conditions include type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea
Cotadutide also led to 2.1 kg body weight loss relative to placebo
Serving patients in Greater Houston Texas, including but not limited to Webster, The Woodlands, Sugar Land, Katy, Friendswood, Pearland, League City, Richmond, Spring, Humble, Kingwood, Stafford, Cypress, Fulshear, Missouri City, River Oaks, Piney Point, Hunters Creek, Bunker Hill, Southside Place, Afton Oaks, Tanglewood, Crestwoods, West University Place, Southside Place, Woodland Heights, Hyde Park, Timbergrove, Montrose, and all other surrounding communities.
Phase 2 retatrutide data suggest approximately 2428% body weight reduction at equivalent timepoints, though Phase 3 confirmation is pending